Please visit answersincme.com/HAC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in gastrointestinal oncology discusses the latest data for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for HER2-directed antibody-drug conjugates in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma; and Translate the latest data for the treatment of gastric and GEJ adenocarcinoma within the context of the current treatment landscape.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related